Levetiracetam Prophylaxis in Brain Tumor Resection Pilot

Launched by HAMILTON HEALTH SCIENCES CORPORATION · Jun 1, 2023

Keywords

ClinConnect Summary

This clinical trial, called the Levetiracetam Prophylaxis in Brain Tumor Resection Pilot, is designed to test whether a medication called levetiracetam can help prevent seizures in patients undergoing surgery to remove a brain tumor. The researchers want to see how feasible it is to conduct a larger study that would compare patients receiving levetiracetam to those who do not, ensuring that neither the patients nor the doctors know who is receiving the medication until the study is finished.

To be eligible for this trial, participants should be adults aged 18 or older who are scheduled for a specific type of brain surgery called craniotomy, where the surgeon removes a tumor located within the brain. However, people with a history of seizures or epilepsy, those currently taking other seizure medications, or those who cannot take levetiracetam for reasons like allergies or difficulty swallowing, will not be able to participate. If you join this study, you can expect careful monitoring and support from the medical team throughout the process, helping to ensure your safety and well-being during this important time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult age 18 years or older
• • Undergoing craniotomy for a brain tumor
• • Intra-axial tumor location
• • Supratentorial tumor location
• Exclusion Criteria:
• • Documented seizure history or epilepsy diagnosis
• • Currently taking an antiepileptic medication
• • Unable to take levetiracetam (e.g. allergy, inability to swallow)
• • Inability to obtain consent from participant or substitute decision maker prior to surgery
• • Renal impairment with eGFR less than 50
• • Pregnancy